|
|
|
Deutivacaftor / Tezacaftor / Vanzacaftor (1)
|
Alyftrek®
|
Vertex Pharmaceuticals (Germany) GmbH
|
Metabolic diseases
|
Cystic fibrosis, at least one non-Class I mutation, aged ≥ 6 years
|
discontinued
Orphan
|
|
|
|
Elosulfase alfa (3)
|
Vimizim®
|
BioMarin Deutschland
|
Metabolic diseases
|
Mucopolysaccharidoses (type IVA)
|
discontinued
Orphan
|
|
|
|
Iptacopan (2)
|
Fabhalta®
|
Novartis Pharma GmbH
|
Genitourinary system diseases
|
Complement-3 glomerulopathy
|
discontinued
Orphan
|
|
|
|
Bulevirtid (3)
|
Hepcludex®
|
Gilead Sciences GmbH
|
Infectious diseases
|
Hepatitis delta virus (HDV) infection, HDV RNA-positive
|
discontinued
Orphan
|
|
|
|
Bulevirtid (2)
|
Hepcludex®
|
Gilead Sciences GmbH
|
Infectious diseases
|
Hepatitis delta virus (HDV) infection, HDV RNA-positive, ≥ 3 to < 18 years, ≥ 10 kg bw
|
discontinued
Orphan
|
|
|
|
Melatonin (2)
|
Slenyto®
|
InfectoPharm Arzneimittel und Consilium GmbH
|
Nervous system diseases
|
Sleep disorders in neurogenetic diseases; ≥ 2 to ≤ 18 years of age
|
discontinued
|
|
|
|
Brentuximab Vedotin (13)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Systemic anaplastic large cell lymphoma; first-line; combination with cyclophosphamide, doxorubicin and prednisone
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (8)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Hodgkin's lymphoma, CD30+, pre-treated
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (9)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Systemic anaplastic large cell lymphoma (sALCL) , relapsed, refractory
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (10)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Hodgkin's lymphoma, CD30+, increased risk of recurrence or progression after transplantation
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (11)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Cutaneous T-cell lymphoma, CD30+, pre-treated
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (12)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Hodgkin's lymphoma, CD30+, first-line, stage III + IV, in combination with doxorubicin, vinblastine and dacarbazine
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (7)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Hodgkin-Lymphoma (CD30+, first-line, stadium III, in combination with Doxorubicin, Vinblastin and Dacarbazin)
|
discontinued
Orphan
|
|
|
|
Idecabtagen vicleucel (2)
|
Abecma®
|
Bristol-Myers Squibb GmbH & Co. KGaA
|
Oncological diseases
|
Multiple myeloma, at least 3 previous therapies
|
discontinued
Orphan (turnover limit)
|
|
|
|
Melphalanflufenamid (2)
|
Pepaxti®
|
Oncopeptides AB
|
Oncological diseases
|
Multiple myeloma, refractory, after 2 prior therapies, combination with dexamethasone
|
discontinued
|
|
|
|
Diroximelfumarat (1)
|
Vumerity®
|
Biogen GmbH
|
Nervous system diseases
|
Multiple Sclerosis (MS)
|
discontinued
|
|
|
|
Belimumab (3)
|
Benlysta®
|
GlaxoSmithKline GmbH & Co. KG
|
Musculoskeletal system diseases
|
Lupus nephritis
|
discontinued
|
|
|
|
Ceftolozan / Tazobactam (4)
|
Zerbaxa®
|
MSD SHARP & DOHME GMBH
|
Infectious diseases
|
Acute pyelonephritis
|
discontinued
|
|
|
|
Ceftolozan / Tazobactam (3)
|
Zerbaxa®
|
MSD SHARP & DOHME GMBH
|
Infectious diseases
|
Complicated urinary tract infections
|
discontinued
|
|
|
|
Ceftolozan / Tazobactam (2)
|
Zerbaxa®
|
MSD SHARP & DOHME GMBH
|
Infectious diseases
|
Complicated intra-abdominal infections
|
discontinued
|
|
|
|
Ceftolozan / Tazobactam (1)
|
Zerbaxa®
|
MSD SHARP & DOHME GMBH
|
Infectious diseases
|
Ospital-acquired pneumonia, ventilator-associated pneumonia
|
discontinued
|
|
|
|
Prasteron (1)
|
Intrarosa®
|
Endoceutics, Inc.
|
Genitourinary system diseases
|
Vulvovaginal atrophy
|
discontinued
|
|
|
|
Ivacaftor (4)
|
Kalydeco®
|
Vertex Pharmaceuticals (Germany) GmbH
|
Metabolic diseases
|
Cystic fibrosis (CF), ≥ 12 years, combination with tezacaftor
|
discontinued
Orphan
|
|
|
|
Daratumumab (2)
|
Darzalex®
|
Janssen Cilag GmbH
|
Oncological diseases
|
Multiple myeloma (MM)
|
discontinued
Orphan
|
|
|
|
Ibrutinib (2)
|
Imbruvica®
|
Janssen-Cilag GmbH
|
Oncological diseases
|
Waldenström's disease
|
discontinued
Orphan
|
|
|
|
Bedaquilin (1)
|
Sirturo®
|
Janssen-Cilag GmbH
|
Infectious diseases
|
Multidrug-resistant pulmonary tuberculosis
|
discontinued
Orphan
|
|
|
|
Denosumab (1)
|
Prolia, XGEVA®
|
Amgen GmbH
|
Musculoskeletal system diseases
|
Osteoporosis (postmenopausal), bone loss (prostate cancer)
|
discontinued
|
|
|
|
Dabigatranetexilat (1)
|
Pradaxa®
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Hematopoietic diseases
|
Prevention of venous thromboembolic events after hip or knee replacement and prevention of stroke and systemic embolism
|
discontinued
|
|
|
|
Rivaroxaban (1)
|
Xarelto®
|
Bayer Vital GmbH
|
Hematopoietic diseases
|
Prophylaxis / therapy of artherotrombotic / venothrombotic events
|
discontinued
|
|
|
|
Saxagliptin (2)
|
Onglyza®
|
Bristol-Myers Squibb GmbH & Co. KGaA und AstraZeneca GmbH
|
Metabolic diseases
|
Diabetes mellitus type 2, monotherapy
|
discontinued
|
|
|
|
Parathyroidhormon (1)
|
Preotact®
|
Takeda GmbH
|
Musculoskeletal system diseases
|
Osteoporosis (postmenopausal)
|
discontinued
|
|
|
|
Retigabin (2)
|
Trobalt®
|
GlaxoSmithKline GmbH & Co. KG
|
Nervous system diseases
|
Epilepsy, focal seizures
|
discontinued
|
